Use of topical corticosteroids, a systemic immune suppressant (cyclosporine), and the recent approval of first-in-class biologics dupilumab (anti-IL-4R), tralokinumab (anti-IL-13), and broad-range small molecule JAK inhibitors (abrocitinib and upadacitinib) for the treatment of moderate to severe AD prove the efficacy of immune-targeted therapies [11,12,13]. The gene discussed is IL13; the disease is Alzheimer disease.